DataMeds AI regains Nasdaq stockholders' equity compliance, per October 19, 2026 notice
Nasdaq notified DataMeds AI on October 19, 2026 that the company has regained compliance with the $2.5 million minimum stockholders' equity requirement under Nasdaq Listing Rule 5550(b)(1). The company had reported a stockholders' deficit of $(12,447,801) in its 2025 annual report, which led to a deficiency letter in April 2026. The company said it could still be subject to delisting if it does not evidence compliance in its next periodic report.
Key points
- Deficiency letter received April 13, 2026, after stockholders' equity of $(12,447,801) was reported for the fiscal year ended December 31, 2025
- Nasdaq notified the company on June 9, 2026 that it had regained bid-price compliance and granted more time on the equity requirement
- Nasdaq compliance notice dated October 19, 2026 confirmed the company met the $2.5 million equity minimum
- Company states it may be subject to delisting if it fails to evidence compliance upon filing its next periodic report
The filing
Written by AI on Nov 9, 2026, 11:46 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 20, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.